Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSRT 1720
说明： Selective SIRT1 activator; induces autophagy and mitochondrial biogenesis
化学名： N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide
纯度： ≥98% (HPLC)
生物活性 for SRT 1720
SRT 1720 is selective SIRT 1 activator (EC50 = 0.16 μM). SRT 1720 inhibits growth of bladder cancer organoids and xenografts (IC50 = 0.35 μM) and induces autophagy. In vitro, SRT 1720 increases mitochondrial biogenesis and recovery after oxidation injury and reduces palmitate-induced insulin resistance. Also improves survival and healthspan of obese mice.
技术数据 for SRT 1720
| 分子量 | 469.56 |
| 公式 | C25H23N7OS |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 925434-55-5 |
| PubChem ID | 24180125 |
| InChI Key | IASPBORHOMBZMY-UHFFFAOYSA-N |
| Smiles | O=C(NC=1C=CC=CC1C=2N=C3SC=C(N3C2)CN4CCNCC4)C5=NC6=CC=CC=C6N=C5 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for SRT 1720
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 2.35 | 5 |
制备储备液 for SRT 1720
以下数据基于产品分子量 469.56。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.05 mM | 42.59 mL | 212.97 mL | 425.93 mL |
| 0.25 mM | 8.52 mL | 42.59 mL | 85.19 mL |
| 0.5 mM | 4.26 mL | 21.3 mL | 42.59 mL |
| 2.5 mM | 0.85 mL | 4.26 mL | 8.52 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for SRT 1720
参考文献 for SRT 1720
参考文献是支持产品生物活性的出版物。
Tan et al (2021) SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene 40 6081 PMID: 34471236
Luo et al (2019) Sirt1 promotes autophagy and inhibits apoptosis to protect cardiomyocytes from hypoxic stress. Int.J.Mol.Med. 43 2033 PMID: 30864731
Paramesha et al (2021) Sirt1 and Sirt3 activation improved cardiac function of diabetic rats via modulation of mitochondrial function. Antioxidants (Basel) 10 338 PMID: 33668369
Funk et al (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J.Pharmacol.Exp.Ther. 333 593 PMID: 20103585
If you know of a relevant reference for SRT 1720, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: SRT 1720, SRT 1720 supplier, SRT1720, SIRT1, sirtuins, activators, organoids, xenografts, autophagy, mitochondria, mitochondrial, oxidation, injury, insulin, resistance, Class, III, HDACs, (Sirtuins), Autophagy, 7558, Tocris Bioscience
篇 SRT 1720 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 SRT 1720 的引用文献。 您是否知道使用了 Tocris SRT 1720 的优秀论文？ 请告知我们.
SRT 1720 的评论
目前没有该产品的评论。 Be the first to review SRT 1720 and earn rewards!
Have you used SRT 1720?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.